Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., MacroGenics Inc, and Seattle Genetics Inc.

2019 Year in Review™: Reflecting on Recent Evidence for the Treatment of Breast Cancer

Release Date: May 15, 2020
Expiration Date: May 15, 2021

Activity Overview

This Year in Review activity will cover noteworthy data reported in 2019 at major society meetings with the potential to impact the care of patients with breast cancer. Recent advances in breast cancer include expanded options in targeted therapies for HER2-positive, triple-negative, and hormone receptor-positive breast cancers, new insights into immunotherapies, and advances in diagnostic testing and personalized care. This activity features a panel of experts who will review the key points of clinical trial design, safety, and efficacy data while contextualizing this new information into optimized patient care. Emerging data across the spectrum of breast cancer management will be reviewed and discussed, from early stage to metastatic disease. The panel of experts will also discuss how they are applying this information to their practices right now, as well as potential future implications.

Acknowledgement of Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., MacroGenics Inc, and Seattle Genetics Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment and management of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals (HCPs) interested in the treatment of cancer may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Consider advances in precision medicine to treat patients with breast cancer.
  • Outline and mitigate adverse events associated with novel therapeutic strategies to improve the outcome of patients with breast cancer.
  • Explain the latest evidence and recommendations for diagnostic testing to improve personalized care for patients with breast cancer.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant/Research Support: Pfizer Inc, Merck & Co Inc, Novartis AG, Eli Lilly and Co, Genentech Inc, OBI Pharma Inc, Odonate Therapeutics Inc, Daiichi Sankyo Company Ltd, Eisai Co Ltd, MacroGenics Inc, and Immunomedics Inc; Other: Travel Support: Daiichi Sankyo Company Ltd, Mylan NV, Pfizer Inc, Merck & Co Inc, AstraZeneca, Novartis AG, and MacroGenics Inc. Other: Honoraria: Puma Biotechnology Inc, Samsung (one-time consulting), and Celltrion (one time only).

Kevin Kalinsky, MD, MS
Kevin Kalinsky, MD, MS
Medical Oncologist, Division of Hematology/Oncology
Herbert Irving Associate Professor of Medicine
Columbia University Herbert Irving Comprehensive Cancer Center
New York-Presbyterian Hospital
New York, NY

Disclosures: Grant/Research Support: Institutional support: Immunomedics Inc, Novartis AG, Incyte Corporation, Genentech Inc/F. Hoffmann-La Roche Ltd, Eli Lilly and Co, Pfizer Inc, Calithera Biosciences Inc, Acetylon, Seattle Genetics Inc, Amgen Inc, Zentalis Pharmaceuticals, CytomX Therapeutics Inc; Consultant: Immunomedics Inc, Biotheranostics, Pfizer Inc, Novartis AG, Eisai Co Ltd, Eli Lilly and Co, Amgen Inc, AstraZeneca; Speakers Bureau: Eli Lilly and Co; Other: Travel: Eli Lilly and Co and AstraZeneca; Commercial Employee Role: Novartis AG, Array BioPharma, Pfizer Inc, and now VP at GRAIL Inc.

Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH
Associate Director
Susan F. Smith Center for Women’s Cancers
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: AstraZeneca, Eli Lilly and Co, Merck & Co Inc, Nektar, Novartis AG, Pfizer Inc, Genentech Inc/F. Hoffmann-La Roche Ltd, Immunomedics Inc, Exelixis Inc, Bristol Myers Squibb Co, Eisai Co Ltd, NanoString Technologies Inc, Cyclacel Pharmaceuticals Inc, Odonate Therapeutics Inc, Seattle Genetics Inc; Consultant: AstraZeneca, Eli Lilly and Co, Merck & Co Inc, Nektar, Novartis AG, Pfizer Inc, Bristol Myers Squibb Co, Eisai Co Ltd, NanoString Technologies Inc, Paxman, Odonate Therapeutics Inc, AbbVie Inc, Anthenex Inc, Oncopep Inc; Advisory Board: AstraZeneca, Eli Lilly and Co, Merck & Co Inc, Nektar, Novartis AG, Genentech Inc/F. Hoffmann-La Roche Ltd, Immunomedics Inc, Bristol Myers Squibb Co, Eisai Co, NanoString Technologies Inc, Puma Biotechnology Inc, Paxman, Silverback Therapeutics, G1 Therapeutics Inc; Other: Travel Expenses: AstraZeneca, Eli Lilly and Co, Merck & Co Inc, Nektar, Novartis AG, Pfizer Inc, Genentech Inc/F. Hoffmann-La Roche Ltd, Immunomedics Inc, Bristol Myers Squibb Co, Eisai Co, NanoString Technologies Inc, Puma Biotechnology Inc, Celldex Therapeutics; Steering Committee: Seattle Genetics Inc.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
27282930
Filter By